Modulation of CCR2 in rheumatoid arthritis: A double‐blind, randomized, placebo‐controlled clinical trial
Open Access
- 24 June 2008
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 58 (7), 1931-1939
- https://doi.org/10.1002/art.23591
Abstract
Objective CCR2 is a chemokine receptor expressed by monocytes, macrophages, and a subset of T cells. Its ligand, CCL2 (monocyte chemotactic protein 1), is abundantly present in the synovium of patients with rheumatoid arthritis (RA). Blocking CCR2 prevents CCL2‐mediated chemotaxis in vitro and modulates arthritis in animal models of RA. In this study we examined the effects of CCR2 blockade on synovial inflammation in RA. Methods The study was designed as a phase IIa clinical trial with a human CCR2 blocking antibody (MLN1202) in patients with active RA. Thirty‐two patients received 3 infusions, over a period of 6 weeks, with either placebo (n = 9) or anti‐CCR2 monoclonal antibody at 0.5 mg/kg (n = 7), 1.5 mg/kg (n = 7), or 4.0 mg/kg (n = 9). Safety was monitored with laboratory tests, immunotoxicity assessments, and documenting of adverse events, and European League Against Rheumatism and American College of Rheumatology response criteria were used to assess clinical improvement. Synovial tissue was obtained at baseline and after 43 days of treatment, for pharmacodynamic analysis using immunohistochemistry and digital image analysis. The Kruskal‐Wallis test was used to compare groups, and the Wilcoxon signed rank test was used to assess changes within the groups. Results All patients completed the study. Treatment with CCR2 blocking antibody reduced the levels of free CCR2 on CD14+ monocytes by at least 57% and up to 94% (P < 0.001), demonstrating the biologic activity of the compound. However, there was no reduction in the levels or expression of any of the synovial biomarkers. Accordingly, no clinical improvement was observed. Conclusion Treatment with anti‐CCR2 blocking antibody did not result in amelioration of synovial inflammation in active RA. The results do not support the notion that blockade of CCR2 may be sufficient to induce clinical improvement in RA.Keywords
This publication has 34 references indexed in Scilit:
- Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sitesJCI Insight, 2007
- Mononuclear phagocytes and rheumatoid synovitis. Mastermind or workhorse in arthritis?Arthritis & Rheumatism, 1997
- Development and validation of the european league against rheumatism response criteria for rheumatoid arthritis: Comparison with the preliminary american college of rheumatology and the world health organization/international league against rheumatism criteriaArthritis & Rheumatism, 1996
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritisArthritis & Rheumatism, 1995
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995
- The MOS 36-Item Short-Form Health Survey (SF-36)Medical Care, 1993
- The health assessment questionnaire 1992. Status and reviewArthritis & Rheumatism, 1992
- Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis.JCI Insight, 1992
- The american college of rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritisArthritis & Rheumatism, 1992
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988